Levacetylmethadol

Also Known As: Levacetylmethadol, Orlaam, levomethadyl acetate

Levacetylmethadol (INN), levomethadyl acetate (USAN), Orlaam (trade name) or levo-α-acetylmethadol (LAAM) is a synthetic opioid similar in structure to methadone. It has a long duration of action due to its active metabolites. It was approved in 1993 by the U.S. Food and Drug Administration for use in the treatment of opioid dependence. In 2001, Orlaam was removed from the European market due to reports of life threatening ventricular rhythm disorders. In 2003, Roxane Laboratories, Inc. discontinued Orlaam in the US.

LAAM is indicated as a second-line treatment for the treatment and management of opioid dependence if patients fail to respond to drugs like methadone or buprenorphine. Before August 1993, LAAM was classified as a schedule I drug in the United States. LAAM is not approved for use in Canada.


Print this Page

All Treatments

Average Effectiveness

This is the Average effectiveness per ailment as reported by our participants (you).

Effectiveness:
  • 0 = No improvement or Worse
  • 1 = Slight improvement
  • 2 = Moderate Improvement
  • 3 = Significant Improvement
  • 4 = Cured

Order By

Type of Treatment

Date Range

Minimum Number of Users

Embed

Complete a survey on Levacetylmethadol to help the CureCrowd community

If you have tried to treat this ailment, please complete the following form to help us better our data, and help guide people to the best possible treatments. CureCrowd is a public resource with absolutely no vested interest in the outcomes of our studies.